The RSI Indicator for AKTX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 36 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Moving Average Convergence Divergence (MACD) for AKTX just turned positive on October 20, 2026. Looking at past instances where AKTX's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.
The 50-day moving average for AKTX moved above the 200-day moving average on October 21, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where AKTX advanced for three days, in 153 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
AKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 41 cases where AKTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AKTX as a result. In 96 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
AKTX moved below its 50-day moving average on October 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AKTX crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AKTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AKTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.862) is normal, around the industry mean (2.973). AKTX's P/E Ratio (95.710) is considerably higher than the industry average of (-1.705). Projected Growth (PEG Ratio) (1.890) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GOVX declined for three days, in 380 of 409 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GOVX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Moving Average Convergence Divergence (MACD) for GOVX just turned positive on September 23, 2026. Looking at past instances where GOVX's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +5.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GOVX advanced for three days, in 157 of 192 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
GOVX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.099) is normal, around the industry mean (2.973). P/E Ratio (-0.038) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.109) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. GOVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GOVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
AKTX | GOVX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 4 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 98 Overvalued | 61 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 59 | 96 | |
P/E GROWTH RATING 1..100 | 4 | 6 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GOVX's Valuation (61) in the null industry is somewhat better than the same rating for AKTX (98) in the Pharmaceuticals Major industry. This means that GOVX’s stock grew somewhat faster than AKTX’s over the last 12 months.
GOVX's Profit vs Risk Rating (100) in the null industry is in the same range as AKTX (100) in the Pharmaceuticals Major industry. This means that GOVX’s stock grew similarly to AKTX’s over the last 12 months.
AKTX's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as GOVX (100) in the null industry. This means that AKTX’s stock grew similarly to GOVX’s over the last 12 months.
AKTX's Price Growth Rating (59) in the Pharmaceuticals Major industry is somewhat better than the same rating for GOVX (96) in the null industry. This means that AKTX’s stock grew somewhat faster than GOVX’s over the last 12 months.
AKTX's P/E Growth Rating (4) in the Pharmaceuticals Major industry is in the same range as GOVX (6) in the null industry. This means that AKTX’s stock grew similarly to GOVX’s over the last 12 months.
| AKTX | GOVX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | N/A |
| Momentum ODDS (%) | 1 day ago 90% | N/A |
| MACD ODDS (%) | 1 day ago 78% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 76% | about 1 month ago 82% |
| Declines ODDS (%) | 1 day ago 90% | 3 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKTX’s FA Score shows that 1 FA rating(s) are green while GOVX’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKTX’s TA Score shows that 6 TA indicator(s) are bullish while GOVX’s TA Score has 3 bullish TA indicator(s).
AKTX (@Biotechnology) experienced а +20.66% price change this week, while GOVX (@Biotechnology) price change was -3.77% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
AKTX is expected to report earnings on Nov 12, 2026.
GOVX is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, AKTX has been loosely correlated with CNTN. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if AKTX jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To AKTX | 1D Price Change % | ||
|---|---|---|---|---|
| AKTX | 100% | -6.05% | ||
| CNTN - AKTX | 34% Loosely correlated | -3.63% | ||
| KPRX - AKTX | 30% Poorly correlated | -2.09% | ||
| QURE - AKTX | 29% Poorly correlated | +1.85% | ||
| GOVX - AKTX | 27% Poorly correlated | -8.40% | ||
| CVKD - AKTX | 25% Poorly correlated | -4.90% | ||
More | ||||
A.I.dvisor indicates that over the last year, GOVX has been loosely correlated with TOVX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if GOVX jumps, then TOVX could also see price increases.
| Ticker / NAME | Correlation To GOVX | 1D Price Change % | ||
|---|---|---|---|---|
| GOVX | 100% | -8.40% | ||
| TOVX - GOVX | 54% Loosely correlated | -3.36% | ||
| GRI - GOVX | 37% Loosely correlated | -3.40% | ||
| OGEN - GOVX | 33% Poorly correlated | -1.82% | ||
| MAIA - GOVX | 32% Poorly correlated | -0.88% | ||
| GANX - GOVX | 29% Poorly correlated | +8.40% | ||
More | ||||